|
Name |
(1R,3R,8R,17R,18E,20Z,24S,25S,26S)-17-[(1S)-1-hydroxyethyl]-13,25-dimethyl-11,22-dioxospiro[2,10,16,23-tetraoxatetracyclo[22.2.1.03,8.08,25]heptacosa-4,12,18,20-tetraene-26,2'-oxirane]-5-carboxylic acid
|
Molecular Formula | C29H36O10 | |
IUPAC Name* |
(1R,3R,8R,17R,18E,20Z,24S,25S,26S)-17-[(1S)-1-hydroxyethyl]-13,25-dimethyl-11,22-dioxospiro[2,10,16,23-tetraoxatetracyclo[22.2.1.03,8.08,25]heptacosa-4,12,18,20-tetraene-26,2'-oxirane]-5-carboxylic acid
|
|
SMILES |
CC1=CC(=O)OC[C@]23CCC(=C[C@H]2O[C@@H]4C[C@@H]([C@]3([C@]45CO5)C)OC(=O)/C=C\C=C\[C@@H](OCC1)[C@H](C)O)C(=O)O
|
|
InChI |
InChI=1S/C29H36O10/c1-17-9-11-35-20(18(2)30)6-4-5-7-24(31)39-21-14-23-29(16-37-29)27(21,3)28(15-36-25(32)12-17)10-8-19(26(33)34)13-22(28)38-23/h4-7,12-13,18,20-23,30H,8-11,14-16H2,1-3H3,(H,33,34)/b6-4+,7-5-,17-12?/t18-,20+,21-,22+,23+,27+,28+,29-/m0/s1
|
|
InChIKey |
AUDNYEHCZOOEAQ-IQEGVICCSA-N
|
|
Synonyms |
Epiroridin acid
|
|
CAS | NA | |
PubChem CID | 139591301 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 544.6 | ALogp: | 1.7 |
HBD: | 2 | HBA: | 10 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 141.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 39 | QED Weighted: | 0.393 |
Caco-2 Permeability: | -5.576 | MDCK Permeability: | 0.00001740 |
Pgp-inhibitor: | 0.02 | Pgp-substrate: | 0.916 |
Human Intestinal Absorption (HIA): | 0.039 | 20% Bioavailability (F20%): | 0.988 |
30% Bioavailability (F30%): | 0.992 |
Blood-Brain-Barrier Penetration (BBB): | 0.488 | Plasma Protein Binding (PPB): | 50.49% |
Volume Distribution (VD): | 0.503 | Fu: | 14.82% |
CYP1A2-inhibitor: | 0.007 | CYP1A2-substrate: | 0.107 |
CYP2C19-inhibitor: | 0.141 | CYP2C19-substrate: | 0.216 |
CYP2C9-inhibitor: | 0.552 | CYP2C9-substrate: | 0.069 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.139 |
CYP3A4-inhibitor: | 0.352 | CYP3A4-substrate: | 0.305 |
Clearance (CL): | 1.81 | Half-life (T1/2): | 0.75 |
hERG Blockers: | 0.331 | Human Hepatotoxicity (H-HT): | 0.621 |
Drug-inuced Liver Injury (DILI): | 0.024 | AMES Toxicity: | 0.044 |
Rat Oral Acute Toxicity: | 0.532 | Maximum Recommended Daily Dose: | 0.95 |
Skin Sensitization: | 0.953 | Carcinogencity: | 0.287 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.014 |
Respiratory Toxicity: | 0.914 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003126 | 0.851 | D0I5DS | 0.231 | ||||
ENC004775 | 0.798 | D0Q4SD | 0.231 | ||||
ENC003173 | 0.690 | D04ATM | 0.229 | ||||
ENC002240 | 0.675 | D0IX6I | 0.226 | ||||
ENC002050 | 0.638 | D0IL7L | 0.226 | ||||
ENC003310 | 0.623 | D0K7HU | 0.226 | ||||
ENC004774 | 0.588 | D09WYX | 0.225 | ||||
ENC004446 | 0.574 | D06XHC | 0.224 | ||||
ENC002696 | 0.571 | D04GJN | 0.222 | ||||
ENC002026 | 0.561 | D0Y7IU | 0.220 |